<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206866</url>
  </required_header>
  <id_info>
    <org_study_id>SMP30</org_study_id>
    <nct_id>NCT03206866</nct_id>
  </id_info>
  <brief_title>Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma</brief_title>
  <official_title>Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the diagnosis and therapy of HCC have being improved, the poor prognosis still&#xD;
      remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it&#xD;
      is important to detect the protein biomarkers which are associated with HCC tumor progression&#xD;
      and may be useful as potential diagnosis or therapeutic targets.&#xD;
&#xD;
      SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiÔ¨Åed&#xD;
      from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular&#xD;
      carcinoma associated antigens [4]&#xD;
&#xD;
      Serum antibody response to SMP30 in various patients using the methods of Western-blot and&#xD;
      ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in&#xD;
      the one with alpha-fetoprotein (AFP) negative&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>serum regucalcin in HCC patients</measure>
    <time_frame>1-12-2016 to 1-12-2017</time_frame>
    <description>This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to:&#xD;
evaluate its potential role as biomarker in diagnosis.&#xD;
evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Role of Serum Regucalcin in Diagnosis of HCC</condition>
  <arm_group>
    <arm_group_label>patients with HCC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hepatitis C Ab positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hepatitis C Ab negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum regucalcin antibody</intervention_name>
    <description>serum regucalcin antibody</description>
    <arm_group_label>patients with HCC</arm_group_label>
    <arm_group_label>patients with hepatitis C Ab negative</arm_group_label>
    <arm_group_label>patients with hepatitis C Ab positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will be subjected to the following:&#xD;
&#xD;
          -  Detailed History taking.&#xD;
&#xD;
          -  Physical examination.&#xD;
&#xD;
          -  Routine laboratory investigations essential for diagnosis and follow up of patients&#xD;
             including:&#xD;
&#xD;
               1. Complete blood count (CBC).&#xD;
&#xD;
               2. Chemistry profile: serum bilirubin-serum albumin-SGPT-SGOT.&#xD;
&#xD;
               3. serum regucalcin(SMP30) antibodies using ELISA&#xD;
&#xD;
               4. AFP level.&#xD;
&#xD;
          -  Radiological assessment:&#xD;
&#xD;
        US, Triphasic CT to assess (tumor site, size, numbers, nodal metastases, distal metastases,&#xD;
        portal vein invasion..)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or&#xD;
             liver biopsy)&#xD;
&#xD;
          2. Adult patients&#xD;
&#xD;
          3. Both genders are eligible.&#xD;
&#xD;
          4. Informed consent obtained from subject or subject's legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with other malignancies.&#xD;
&#xD;
          2. Patients with advanced comorbidities except for renal failure.&#xD;
&#xD;
          3. Prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncology Center Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maha zaafarany, professor</last_name>
      <phone>01001996798</phone>
    </contact>
    <contact_backup>
      <last_name>sameh samaa, professor</last_name>
      <phone>01001009510</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://ocmu.mans.edu.eg/en/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed_Elalfy</investigator_full_name>
    <investigator_title>medical oncology resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

